OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment

BACKGROUND: Multiple myeloma (MM) patients are immunocompromised due to defects in humoral/cellular immunity and immunosuppressive therapy. Reports indicate that the antibody (Ab) response in MM after 1 dose of SARS-CoV-2 RNA vaccine is attenuated. Vaccine response kinetics in patients with prior CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Oekelen, Oliver Van, Agte, Sarita, Gleason, Charles, Srivastava, Komal, Beach, Katherine, Aleman, Adolfo, Upadhyaya, Bhaskar, Kappes, Katerina, Mouhieddine, Tarek, Wang, Bo, Chari, Ajai, Cordon-Cardo, Carlos, Krammer, Florian, Jagannath, Sundar, Simon, Viviana, Wajnberg, Ania, Parekh, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580177/
http://dx.doi.org/10.1016/S2152-2650(21)02122-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580177/
http://dx.doi.org/10.1016/S2152-2650(21)02122-4

Ejemplares similares